QGEN
Qiagen N.V.
Is QGEN Halal?
Sample and assay technologies for molecular diagnostics with permissible business.
What You Should Know
QIAGEN provides sample-preparation, assay, molecular-diagnostics, genomics and bioinformatics technologies. Its March 31, 2026 Form 6-K quarterly report reports $5,782.065 million of assets, $1,646.557 million of long-term debt, $646.289 million of cash, $396.616 million of receivables and $492.320 million of quarterly net sales. Debt/assets is 28.48%, liquidity/assets is 11.18%, receivables-plus-cash/assets is 18.04% and disclosed interest income is 2.15% of revenue; the examined FTSE, MSCI and Malaysia asset ratios pass, while market-cap methods remain uncalculated.
⚠️ Concerns
- •Clinical and forensic customer end uses
- •Genomics and bioinformatics applications
- •Interest-bearing debt
- •Interest income
Current quantitative Sharia screen
Based on 6-K figures for the period ended 2026-03-31; calculated 2026-07-15.
1,646.557 / 5,782.065
646.289 / 5,782.065
1,042.905 / 5,782.065
10.562 / 492.32
- Financial
- Pass
- Overall
- Pass
Debt/assets is 28.48%, liquidity/assets is 11.18%, receivables-plus-cash/assets is 18.04% and disclosed interest income is 2.15% of revenue; examined FTSE ratios and core activity pass.
- Financial
- Pass
- Overall
- Pass
Debt/assets, liquidity/assets and receivables-plus-cash/assets are below the examined MSCI total-assets limits; this is not an index-membership claim.
- Financial
- Pass
- Overall
- Pass
Debt/assets and liquidity/assets are below the examined Malaysia limits; this is a calculation, not an official classification.
- Financial
- Not calculated
- Overall
- Incomplete
A properly licensed historical market-cap series is not stored; filing-based asset ratios remain documented.
Business-activity disclosure
QIAGEN develops sample-preparation, assay, molecular-diagnostics, genomics and bioinformatics technologies. The core life-sciences activity is generally permissible.
Limitation: The filing does not classify every clinical, forensic, pharmaceutical or research end use into a scholar-approved prohibited-revenue numerator.
Purification
QIAGEN discloses $10.562 million of interest income, but does not provide a scholar-approved purification percentage or separate prohibited-activity numerator.
Inputs, assumptions and primary sources
- Amounts are USD millions converted from QIAGEN's March 31, 2026 U.S. GAAP quarterly report filed on Form 6-K.
- Long-term debt is $1,646.557 million; no current debt is reported in the selected balance-sheet captions.
- Cash is $646.289 million. Short-term investments were zero at March 31, 2026, so no interest-bearing-securities proxy is added.
- Accounts receivable are $396.616 million net; quarterly net sales are $492.320 million and disclosed interest income is $10.562 million.
- Sample, assay, molecular-diagnostics and genomics technologies are generally permissible, while customer end uses require qualitative review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar Stocks
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →